Dyne Therapeutics (DYN) vs Enliven Therapeutics (ELVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Enliven Therapeutics (ELVN) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 105.7% versus a gain of 14.5%. Over five years, ELVN leads with a +182.5% price change compared with +7.3% for DYN. Enliven Therapeutics is the larger company by market cap ($3.03 billion vs $2.98 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | ELVN |
|---|---|---|
| Share price | $15.97 | $41.36 |
| Market cap | $2.98B | $3.03B |
| 1-day change | +3.70% | -2.43% |
| YTD return | -18.35% | +168.57% |
| 1-year return | +14.48% | +105.67% |
| 5-year return | +7.33% | +182.51% |
| EPS (TTM) | $-3.30 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-446.21M | $-103.69M |
| 52-week high | $27.31 | $62.32 |
| 52-week low | $13.73 | $14.79 |
| Distance from 52-week high | -41.51% | -33.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +125.42% | +78.12% |
| Average volume | 2.78M | 1.12M |
| Shares outstanding | 186.75M | 73.27M |
| Employees | 289 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELVN has outperformed DYN by 91.2 percentage points over the past year.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
DYN vs ELVN FAQ
Which is bigger, Dyne Therapeutics or Enliven Therapeutics?
Enliven Therapeutics (ELVN) is larger, with a market capitalization of $3.03B compared with $2.98B for Dyne Therapeutics (DYN).
Which stock has performed better over the past year, DYN or ELVN?
ELVN returned +105.67% over the past 12 months, compared with +14.48% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and Enliven Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.